Blackstone, KKR Said to Ready Financing for Valeant’s INovaBy
Blackstone Group LP, Carlyle Group LP and KKR & Co. are among buyout firms in talks with banks for financing to back their bids for Valeant Pharmaceutical International Inc.’s Australian drug unit, people with knowledge of the matter said.
Indicative bids for Valeant’s iNova Pharmaceuticals business were submitted this month, according to the people, who asked not to be identified because they aren’t authorized to speak publicly. The sale may fetch about A$1 billion ($773 million), the people said…
Leave a Reply
You must be logged in to post a comment.